To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
NCT01223898
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Myeloid Leukemia
Interventions
DRUG:
Tasigna
Sponsor
Novartis Pharmaceuticals